Q4 2016 13F Holders as of 12/31/2016
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
131M
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
8.62M
-
Shares change
-
+4.39M
-
Total reported value, excl. options
-
$18.1M
-
Value change
-
+$8.66M
-
Put/Call ratio
-
0.65
-
Number of buys
-
16
-
Number of sells
-
-7
-
Price
-
$2.10
Significant Holders of Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) as of Q4 2016
30 filings reported holding AUPH - Aurinia Pharmaceuticals Inc. - Common Shares, no par value as of Q4 2016.
Aurinia Pharmaceuticals Inc. - Common Shares, no par value (AUPH) has 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.62M shares
of 131M outstanding shares and own 6.6% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (4.07M shares), GOLDMAN SACHS GROUP INC (1.27M shares), ACUTA CAPITAL PARTNERS, LLC (1M shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (894K shares), Anson Funds Management LP (388K shares), SG Americas Securities, LLC (373K shares), K2 PRINCIPAL FUND, L.P. (202K shares), OXFORD ASSET MANAGEMENT (101K shares), UBS Group AG (98.9K shares), and MILLENNIUM MANAGEMENT LLC (70.7K shares).
This table shows the top 21 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.